Citadel Advisors’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Citadel Advisors’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,262	Closed	-$22.2K	–	15514
2023 Q2	$22.2K	Buy	+12,262	New	+$22.4K	﹤0.01%	12636
2022 Q1	–	Sell	-300,000	Closed	-$4.91M	–	14966
2021 Q4	$4.91M	Sell	300,000 -6,767	-2%	-$78.7K	﹤0.01%	4322
2021 Q3	$3.05M	Sell	306,767 -167,544	-35%	-$1.66M	﹤0.01%	5326
2021 Q2	$4.74M	Sell	474,311 -247,455	-34%	-$2.48M	﹤0.01%	4562
2021 Q1	$7.19M	Buy	+721,766	New	+$7.46M	﹤0.01%	3522

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's PRDS Position: Q3 2023 in Review

Citadel Advisors sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 12,262 shares — an estimated $22.2K sold.

Citadel Advisors first reported a position in PRDS in Q1 2021 and held it in 5 quarters. The position peaked at $7.19M in Q1 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Citadel Advisors reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 12,262 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $22.2K.
Citadel Advisors first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Citadel Advisors's Pardes Biosciences, Inc. Common Stock position peaked at $7.19M in Q1 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.